Laboratorios Farmaceuticos Rovi, S.A. (LABFF)
USD 90.61
(0.0%)
USD 90.61
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 263.09 Million EUR | 3.13% |
| 2022 | 263.76 Million EUR | 29.72% |
| 2021 | 203.33 Million EUR | 24.08% |
| 2020 | 163.88 Million EUR | -4.46% |
| 2019 | 171.52 Million EUR | 9.16% |
| 2018 | 157.13 Million EUR | 5.81% |
| 2017 | 148.5 Million EUR | 18.95% |
| 2016 | 124.84 Million EUR | -1.77% |
| 2015 | 127.09 Million EUR | 9.77% |
| 2014 | 115.77 Million EUR | 7.98% |
| 2013 | 107.22 Million EUR | 2.37% |
| 2012 | 104.73 Million EUR | 8.78% |
| 2011 | 96.28 Million EUR | 37.9% |
| 2010 | 69.82 Million EUR | 37.08% |
| 2009 | 50.93 Million EUR | 52.07% |
| 2008 | 33.49 Million EUR | -35.26% |
| 2007 | 51.74 Million EUR | 2.61% |
| 2006 | 50.42 Million EUR | -100.0% |
| 2005 | 2420.37 Billion EUR | 112643.26% |
| 2004 | 2.14 Billion EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 73.11 Million EUR | 10.16% |
| 2024 Q1 | 66.38 Million EUR | -7.56% |
| 2023 Q4 | 71.82 Million EUR | 5.69% |
| 2023 Q2 | 66.95 Million EUR | 2.53% |
| 2023 FY | 272.03 Million EUR | 3.13% |
| 2023 Q3 | 67.95 Million EUR | 1.5% |
| 2023 Q1 | 65.3 Million EUR | -15.6% |
| 2022 Q4 | 77.37 Million EUR | 20.08% |
| 2022 Q1 | 56.06 Million EUR | -7.58% |
| 2022 FY | 263.76 Million EUR | 29.72% |
| 2022 Q3 | 64.43 Million EUR | -2.21% |
| 2022 Q2 | 65.89 Million EUR | 17.53% |
| 2021 Q4 | 60.65 Million EUR | 16.29% |
| 2021 Q1 | 40.23 Million EUR | -9.83% |
| 2021 Q2 | 50.27 Million EUR | 24.94% |
| 2021 Q3 | 52.16 Million EUR | 3.76% |
| 2021 FY | 203.33 Million EUR | 24.08% |
| 2020 FY | 163.88 Million EUR | -4.46% |
| 2020 Q1 | 39.82 Million EUR | -19.62% |
| 2020 Q4 | 44.62 Million EUR | 10.4% |
| 2020 Q2 | 39.01 Million EUR | -2.02% |
| 2020 Q3 | 40.42 Million EUR | 3.6% |
| 2019 Q1 | 39.08 Million EUR | -12.41% |
| 2019 Q2 | 44.64 Million EUR | 14.23% |
| 2019 FY | 171.52 Million EUR | 9.16% |
| 2019 Q4 | 49.54 Million EUR | 29.5% |
| 2019 Q3 | 38.25 Million EUR | -14.31% |
| 2018 Q4 | 44.61 Million EUR | 25.22% |
| 2018 FY | 157.13 Million EUR | 5.81% |
| 2018 Q3 | 35.63 Million EUR | -12.26% |
| 2018 Q2 | 40.6 Million EUR | 11.95% |
| 2018 Q1 | 36.27 Million EUR | -20.63% |
| 2017 Q2 | 31.62 Million EUR | -6.66% |
| 2017 Q1 | 33.88 Million EUR | -7.0% |
| 2017 FY | 148.5 Million EUR | 18.95% |
| 2017 Q4 | 45.7 Million EUR | 22.55% |
| 2017 Q3 | 37.29 Million EUR | 17.92% |
| 2016 Q3 | 32.21 Million EUR | 5.69% |
| 2016 Q2 | 30.47 Million EUR | 18.5% |
| 2016 FY | 124.84 Million EUR | -1.77% |
| 2016 Q4 | 36.43 Million EUR | 13.11% |
| 2016 Q1 | 25.72 Million EUR | -29.14% |
| 2015 Q3 | 31.94 Million EUR | 4.44% |
| 2015 Q1 | 28.25 Million EUR | -18.55% |
| 2015 FY | 127.09 Million EUR | 9.77% |
| 2015 Q4 | 36.29 Million EUR | 13.62% |
| 2015 Q2 | 30.59 Million EUR | 8.26% |
| 2014 Q1 | 27.25 Million EUR | -4.12% |
| 2014 FY | 115.77 Million EUR | 7.98% |
| 2014 Q3 | 27.7 Million EUR | 6.05% |
| 2014 Q4 | 34.68 Million EUR | 25.2% |
| 2014 Q2 | 26.12 Million EUR | -4.15% |
| 2013 Q2 | 27.32 Million EUR | 11.05% |
| 2013 Q3 | 26.86 Million EUR | -1.7% |
| 2013 Q4 | 28.42 Million EUR | 5.83% |
| 2013 FY | 107.22 Million EUR | 2.37% |
| 2013 Q1 | 24.6 Million EUR | -54.08% |
| 2012 Q2 | 25.61 Million EUR | 0.31% |
| 2012 FY | 104.73 Million EUR | 8.78% |
| 2012 Q3 | 26.96 Million EUR | 5.27% |
| 2012 Q4 | 53.58 Million EUR | 98.71% |
| 2012 Q1 | 25.53 Million EUR | -49.52% |
| 2011 Q2 | 22.97 Million EUR | 1.06% |
| 2011 Q3 | 24.66 Million EUR | 7.37% |
| 2011 FY | 96.28 Million EUR | 37.9% |
| 2011 Q4 | 50.58 Million EUR | 105.09% |
| 2011 Q1 | 22.72 Million EUR | -15.03% |
| 2010 Q4 | 26.74 Million EUR | 52.44% |
| 2010 Q1 | 15.99 Million EUR | 0.0% |
| 2010 Q2 | 9.53 Million EUR | -40.41% |
| 2010 FY | 69.82 Million EUR | 37.08% |
| 2010 Q3 | 17.54 Million EUR | 84.07% |
| 2009 FY | 50.93 Million EUR | 52.07% |
| 2008 FY | 33.49 Million EUR | -35.26% |
| 2007 FY | 51.74 Million EUR | 2.61% |
| 2006 FY | 50.42 Million EUR | -100.0% |
| 2005 FY | 2420.37 Billion EUR | 112643.26% |
| 2004 FY | 2.14 Billion EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 3.65 Million USD | -7106.549% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -19510.971% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -9912.856% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -790.231% |
| GB Sciences, Inc. | 1.42 Million USD | -18420.826% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -7626.626% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -119443.98% |
| Skye Bioscience, Inc. | 13.54 Million USD | -1841.975% |
| Zenith Capital Corp. | 8.94 Million USD | -2841.854% |
| Agentix Corp. | 1.37 Million USD | -19079.067% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -5117.924% |
| Biomind Labs Inc. | 994.18 Thousand USD | -26362.962% |
| ContraFect Corporation | 56.88 Million USD | -362.462% |
| CSL Limited | 3.44 Billion USD | 92.372% |
| CytoDyn Inc. | 18.05 Million USD | -1356.917% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -14011.469% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -67434.128% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -358.026% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -63222.093% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -17417.157% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -28388.051% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -606.174% |
| SQZ Biotechnologies Company | 85.61 Million USD | -207.28% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -12741.771% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -203.151% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -8921.564% |
| Mesoblast Limited | 5.9 Million USD | -4357.641% |
| Marizyme, Inc. | 19.23 Million USD | -1267.424% |
| Genus plc | 147.7 Million USD | -78.125% |
| Pharming Group N.V. | 225.49 Million USD | -16.674% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -3054.935% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -17691.354% |
| IMV Inc. | 37.7 Million USD | -597.681% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -9328.543% |
| MultiCell Technologies, Inc. | 567.42 USD | -46365907.543% |
| ONE Bio Corp. | 6.44 Million USD | -3982.781% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -206.114% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -964.495% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -14851.031% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -3816.187% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 1052460.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -1543.261% |
| Alpha Cognition Inc. | 9.7 Million USD | -2610.703% |
| Enzolytics Inc. | 2.17 Million USD | -11971.078% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 82.844% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -25100.192% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -10839.593% |
| Genscript Biotech Corporation | 825.34 Million USD | 68.124% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -5249.627% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -100421.156% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -10615.113% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -153297.198% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -13596.141% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -2896.731% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -5867.557% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | -6922.439% |
| Helix BioMedix, Inc. | 1.97 Million USD | -13241.048% |
| EV Biologics, Inc. | 531.96 Thousand USD | -49356.54% |
| Q BioMed Inc. | 3.43 Million USD | -7555.469% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -2320.999% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -164.864% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | -1045.124% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -14236.587% |
| HST Global, Inc. | 140.9 Thousand USD | -186611.803% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -19600.756% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -23287.649% |
| Halberd Corporation | 74.84 Thousand USD | -351427.217% |
| Resverlogix Corp. | 12.71 Million USD | -1969.619% |
| Cell Source, Inc. | 4.32 Million USD | -5982.519% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -16558.066% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | -3498.912% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -1510088.853% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -10565.403% |
| Kadimastem Ltd | 2.41 Million USD | -10816.09% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -6107.275% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -144865.149% |
| LadRx Corporation | 3.81 Million USD | -6802.005% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -28388.051% |
| Affymax, Inc. | 39.38 Million USD | -567.978% |
| Itoco Inc. | 919.14 Thousand USD | -28523.402% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -23411.171% |
| Mobile Lads Corp. | 554.54 Thousand USD | -47342.412% |
| International Stem Cell Corporation | 5.27 Million USD | -4891.273% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.82 Million USD | -6786.908% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -1045193.814% |
| Qrons Inc. | 643.67 Thousand USD | -40772.984% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -18430.179% |
| SYBLEU INC | 160.87 Thousand USD | -163435.891% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -11698.398% |
| Rebus Holdings, Inc. | 664 Thousand USD | -39521.988% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -14384.782% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -499672.045% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -1293170.412% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -625.445% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -16160.198% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -35653.939% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -8356.766% |
| Neutra Corp. | 243.82 Thousand USD | -107802.929% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -1407.075% |
| PureTech Health plc | 144.59 Million USD | -81.947% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -1183.999% |
| IXICO plc | 4.7 Million USD | -5489.335% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -2890.679% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -123.435% |
| CSL Limited | 3.89 Billion USD | 93.242% |
| Cellectis S.A. | 97.32 Million USD | -170.335% |